Faster Drug Approvals by FDA Raise Concerns About Transparency and Beneficence in Clinical Trials

With recent studies from Oregon State University raising essential points about drug safety and research transparency in an era when the U.S. Food and Drug Administration seems to be approving drugs after fewer trials (accelerated approval) and releasing less data from those trials, one experienced principal investigator cautions that public perceptions of clinical research may take a hit.